Buys | $48,970 | 4 | 100 |
Sells | $0 | 0 | 0 |
Magovcevic-Liebisch Ivana | President and CEO | 3 | $28,450 | 0 | $0 | $28,450 |
Budd Haeberlein Samantha L. | director | 1 | $20,520 | 0 | $0 | $20,520 |
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral …
Over the last 12 months, insiders at Vigil Neuroscience, Inc. have bought $48,970 and sold $0 worth of Vigil Neuroscience, Inc. stock.
On average, over the past 5 years, insiders at Vigil Neuroscience, Inc. have bought $17.69M and sold $4,200 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Magovcevic-Liebisch Ivana (President and CEO) — $28,450. Budd Haeberlein Samantha L. (director) — $20,520.
The last purchase of 5,000 shares for transaction amount of $8,400 was made by Magovcevic-Liebisch Ivana (President and CEO) on 2024‑12‑19.
2024-12-19 | Magovcevic-Liebisch Ivana | President and CEO | 5,000 0.0123% | $1.68 | $8,400 | +38.55% | ||
2024-12-19 | Budd Haeberlein Samantha L. | director | 12,000 0.0301% | $1.71 | $20,520 | +38.55% | ||
2024-12-18 | Magovcevic-Liebisch Ivana | President and CEO | 5,000 0.0124% | $1.67 | $8,350 | +36.97% | ||
2024-12-05 | Magovcevic-Liebisch Ivana | President and CEO | 5,000 0.0125% | $2.34 | $11,700 | -3.46% | ||
2023-11-20 | Magovcevic-Liebisch Ivana | President and CEO | 4,000 0.0114% | $3.75 | $15,000 | -6.85% | ||
2022-11-18 | Sale | Papapetropoulos Spyros | Chief Medical Officer | 300 0.001% | $14.00 | $4,200 | -27.54% | |
2022-05-16 | Thorp Clay | 14,893 0.0551% | $2.97 | $44,189 | +235.79% | |||
2022-05-05 | Thackaberry Evan | SVP, Head of Early Development | 1,500 0.0064% | $4.00 | $6,000 | +185.03% | ||
2022-05-03 | Ziolkowski Jennifer Lynn | Chief Financial Officer | 4,000 0.0149% | $3.77 | $15,098 | +163.16% | ||
2022-05-03 | Verni Christopher | General Counsel | 4,000 0.0148% | $3.77 | $15,074 | +163.16% | ||
2022-05-03 | Papapetropoulos Spyros | Chief Medical Officer | 4,000 0.0134% | $3.40 | $13,591 | +163.16% | ||
2022-05-02 | Magovcevic-Liebisch Ivana | President and CEO | 4,000 0.0141% | $3.61 | $14,439 | +160.99% | ||
2022-03-28 | Thorp Clay | 3,000 0.0114% | $7.20 | $21,604 | +25.92% | |||
2022-01-11 | Vitorovic Stefan | director | 1.68M 7.4164% | $14.00 | $23.45M | -24.96% | ||
2022-01-11 | Vida Ventures GP III, L.L.C. | 10 percent owner | 1.68M 7.4164% | $14.00 | $23.45M | -24.96% | ||
2022-01-11 | Booth Bruce | director | 535,000 2.3688% | $14.00 | $7.49M | -24.96% | ||
2022-01-11 | Atlas Venture Fund XII, L.P. | 10 percent owner | 535,000 2.3688% | $14.00 | $7.49M | -24.96% | ||
2022-01-11 | Thorp Clay | director | 265,000 1.1733% | $14.00 | $3.71M | -24.96% | ||
2022-01-11 | Northpond Ventures GP, LLC | 10 percent owner | 355,000 1.5718% | $14.00 | $4.97M | -24.96% |
Magovcevic-Liebisch Ivana | President and CEO | 222687 0.5447% | $449,827.74 | 5 | 0 | +77.07% |
Budd Haeberlein Samantha L. | director | 12000 0.0294% | $24,240.00 | 1 | 0 | |
Vitorovic Stefan | director | 5004393 12.2418% | $10.11M | 1 | 0 | <0.0001% |
Vida Ventures GP III, L.L.C. | 10 percent owner | 5004393 12.2418% | $10.11M | 1 | 0 | <0.0001% |
Booth Bruce | director | 4808896 11.7636% | $9.71M | 1 | 0 | <0.0001% |
$4,919,189 | 138 | 5.22% | $95.3M | |
$49,091,668 | 110 | 13.11% | $83.06M | |
$155,580,641 | 77 | -24.21% | $86.51M | |
$4,898,715 | 46 | 40.74% | $73.28M | |
$329,102,560 | 42 | 30.96% | $73.82M |
Increased Positions | 30 | +51.72% | 3M | +12.36% |
Decreased Positions | 23 | -39.66% | 5M | -16.14% |
New Positions | 11 | New | 2M | New |
Sold Out Positions | 12 | Sold Out | 3M | Sold Out |
Total Postitions | 65 | +12.07% | 27M | -3.78% |
Atlas Venture Life Science Advisors, Llc | $11,790.00 | 12.42% | 5.84M | 0 | 0% | 2024-12-31 |
Northpond Ventures, Llc | $8,513.00 | 8.97% | 4.21M | 0 | 0% | 2024-09-30 |
Siren, L.L.C. | $4,022.00 | 4.24% | 1.99M | 0 | 0% | 2024-12-31 |
Bvf Inc/Il | $3,664.00 | 3.86% | 1.81M | 0 | 0% | 2024-12-31 |
Citadel Advisors Llc | $3,045.00 | 3.21% | 1.51M | +64,724 | +4.49% | 2024-12-31 |
Sphera Funds Management Ltd. | $3,035.00 | 3.2% | 1.5M | -145,175 | -8.81% | 2024-12-31 |
683 Capital Management, Llc | $2,828.00 | 2.98% | 1.4M | +180,420 | +14.79% | 2024-12-31 |
Vanguard Group Inc | $1,970.00 | 2.08% | 975,473 | +70,742 | +7.82% | 2024-12-31 |
Ensign Peak Advisors, Inc | $1,420.00 | 1.5% | 703,116 | +97,580 | +16.11% | 2024-12-31 |
Pivotal Bioventure Partners Investment Advisor Llc | $1,132.00 | 1.19% | 560,595 | 0 | 0% | 2024-12-31 |